chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Arm pain, which was not noted as unusual post-vaccination, initially. The arm soreness persisted over the next few weeks and never subsided. It gradually become worse and caused increasing pain and subsequent decrease of mobility  to my left arm and shoulder. The most painful area was and continues to be between the top of my left shoulder to my elbow-lateral aspect. My shoulder is also painful, but I'm not sure if it is due to radiating pain from the arm. The MRI I had did indicate some non-surgical pathology in my shoulder (impingement syndrome and inflammation). In early  March, I saw my PCM, and received a referral to orthopedics and for an MRI, as the pain and immobility wasn't resolving.
Redness, rash, and swelling around injection site migrating to adjacent areas of the upper arm associated with severe itching.  This began 9 days after injection and has continued for 6 days and is on-going at this time. Doctor has prescribed cold compresses and Ultravate topical lotion.
After receiving vaccines patient complained of lightheadedness. Lasted approx. 5 minutes. Patient laid on exam table, legs propped up. Cup of water given.
pt recv vax 6JAN98 & 22JAN98 exp a rash, one on back & 3 @ the inj site;
Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 09-FEB-2022; Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 09-FEB-2022; This spontaneous case was reported by an emergency medical technician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 09-FEB-2022) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 09-FEB-2022) in a 32-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Feb-2022 at 7:09 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 09-Feb-2022 at 7:09 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 09-FEB-2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 09-FEB-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 09-FEB-2022) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 09-FEB-2022) outcome was unknown. Not Provided. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments. No concomitant product reported by reporter. No treatment information was provided.
Patient developed a generalized rash 9 days after MMR vaccine. C/o hematoma on Right thigh injection site occured same day of vaccines given.
Pt previously received Janssen COVID vaccine 5mins post vaccination pt reported dizziness. Vitals: 119/74, 82, 18 Pt stable and released from the vaccination site.
Tachycardia and chest pain 25 minutes following vaccine administration.  Symptoms spontaneously resolved after 2-3 hours.
SHE HAS HAD MANY ANAPHYLAXIS REACTIONS BEFORE SO BEFORE THE VACCINE SHE TOOK 1 BENDARYL CAPSULE 25MG BEFORE SHE RECEIVED THE VACCINE. SHE TOOK 1 MORE CAPSULE AFTER SHE RECEIVED THE VACCINE. 1 HOUR LATER SHE STARTING GETTING A LITTLE BIT OF CHEST PAIN SO WE GAVE HER 1 MORE BENADRYL, AND WE MONITORED HER FOR 2 HOURS AND THEN SHE FELT BACK TO NORMAL AND LEFT THE CLINIC.
patient was administered 0.5 ml dose of BNT162B2 by accident, more than the recommended dose of the vaccine; arm soreness; This is a spontaneous report via Medical information team from a contactable nurse who reported similar events for 3 patients. This is the 3rd of 3 reports. A 41 year old patient of unspecified gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on an unspecified date, at 0.5 ml single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. On an unspecified date, the patient was administered 0.5 ml dose of BNT162B2 by accident, more than the recommended dose of the vaccine, as they thought they were administering the Moderna vaccine. Upon follow up on 07Jan2021, it was reported that a nurse in the vaccination clinic inadvertently administered 0.5 ml of the Pfizer vaccine to 3 patients. The nurse stated the patient was fine, only experienced a little arm soreness after receiving the vaccine. The outcome of the event was unknown.     Information on the lot/batch number has been requested.  Follow-up (07Jan2021 and 08Jan2021): New information received from a contactable nurse includes: patient information (patient's age added) and course information.  Information on the lot/batch number has been requested.  Follow-Up (11Feb2021): Follow-up attempts are completed. No further information is expected.  Follow up (19Feb2021): New information from a contactable nurse includes new non serious event (arm soreness).   No follow-up attempts are possible; information about lot/batch number cannot be obtained.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021010188 same reporter, event, product, different patient
Initial report was received 23 September 2013 from a consumer. A 12-month-old male patient received Influenza vaccine (manufacturer unknown) and Varicella vaccine (other manufacturer); lot numbers, routes, sites and dates of administration not reported, and an unspecified amount of time later, the patient developed intussusception leading to hospitalization (dates not reported). The patient was seen by a GI physician and an immunologist. Outcome was not reported. This patient previously experienced "crying for days" after receiving DTAP, RV, HIB and IPOL vaccines at two, four and six months of age (captured in case number 2013-09796). This patient experienced a subsequent event after receiving DTAP vaccine at 2 years of age (captured in case number 2013-09797). Documents held by sender: None.
DOUBLE VISION 4 HOURS LATER , ALSO AT 22, 30, 55 AND 60 HOURS AFTER VACCINATION  RESTED, CLOSED EYES TILL IT SUBSIDED       EACH TIME THE DURATION WAS SHORTER
I am not sure if it's from the vaccine. I got sick for days following each of my vaccines. Brain fog that has never gone away. But I also contracted covid twice. So I don't know if it's actually from the vaccine or from the virus it's self. I have severe cognitive issues. Short term memory loss, speech and memory problems. Muscle weakness and fatigue. It comes and goes in spurts. Some days are better than others.
Difficulty swallowing, throat constriction,  chest tightness ( that I never have  normally), had to use rescue inhaler ( which I never use) every four hours. Started taking Benadryl per physicians advice.  Symptioms continued  into the day after.
This spontaneous report was received from a registered nurse referring to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, drug reactions/allergies or concomitant medications were not provided. In November 2017, also reported as "the date between 08-NOV-2017 to 14-NOV-2017", the patient received one separate dose of improperly stored PNEUMOVAX 23 Lot # N010105, expiry date on 15-NOV-2018, for prophylaxis (strength and route were not reported). The vaccine was stored at a temperature at or above 32°F (Farenheit) to 35°F during 15 minutes. No previous temperature excursions were reported and the call was because of a data logger. No adverse effects were reported. This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1711USA006632:
COVID-19 Treatment; COVID-19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  An 83-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 07Apr2022 at 09:15 as dose 4 (booster), single (Lot number: FM0698) at the age of 82 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "tachy/brady syndrome" (unspecified if ongoing); "tachy/brady syndrome" (unspecified if ongoing); "chronic hypothyroidism" (unspecified if ongoing); "mild hypertension" (ongoing); "Known allergies: sulfonamides" (unspecified if ongoing); "Known allergies: scallops" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Jun2022, outcome "unknown" and all described as "COVID-19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical information: The patient was treated with Paxlovid from 13Jun2022 to 17Jun2022. The patient did not received any other medication in 2 weeks.
No adverse event; Moderna COVID-19 vaccine: first dose was 5 months ago; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTRATION INTERRUPTED (Moderna COVID-19 vaccine: first dose was 5 months ago) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication.    No Medical History information was reported.   In 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient started TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) at an unspecified dose. In 2021, the patient experienced PRODUCT ADMINISTRATION INTERRUPTED (Moderna COVID-19 vaccine: first dose was 5 months ago). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT ADMINISTRATION INTERRUPTED (Moderna COVID-19 vaccine: first dose was 5 months ago) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for PRODUCT ADMINISTRATION INTERRUPTED (Moderna COVID-19 vaccine: first dose was 5 months ago).    No concomitant medications were reported. No treatment medications were reported. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   Reporter did not allow further contact
Site was cleansed with alcohol pad, injection was given 2 finger widths below head of left humerus using a 25G 1 inch needle. Injection was tolerated well. Band-aid applied. Patient reported back to clinic with complaint of left shoulder pain which started 2 days after the injections was given. She had tried heat and cold therapy and a oriental cream (she was not aware of the name). Patient was recommended to begin taking anti-inflammatory. Phone call to the patient 01/09/23, she stated anti-inflammatory had help some. Recommended if pain continues to see orthopedist for imaging and/or possible steroid injection, or other recommendations
An itchy rash with welts appeared on my thighs and underarms.  In addition, my neck and ears turned red.  I took a shower and 2 tablets of Benadryl Allergy prior to going to sleep.  I also contacted my primary care physician, who instructed me the next morning to continue taking one tablet of Benadryl every 6 hours.  The redness around my neck and ears was gone the next morning and the rash on my inner thighs started to disappear.  However, when I let more than 6-8 hours laps between doses of Benadryl, I would feel the itch start to return throughout my body.  This continued for roughly one week.  As of today it appears that the rash is gone and I am no longer taking Benadryl on a regular basis.  If necessary, I have pictures of the rash from the initial onset.
Vaccine administered in error. Notified the Dept of Health and they advised us on her plan - will need another MENACTRA booster prior to college (up to 18 years old).
BlurredVision, Employee describes blurred vision in left eye 2 days after vaccine. Went to eye doctor and was diagnosed with cataract not related to aging process Narrative: Employee was told she could choose to have cataract removed as eye ointment had not been successful in treating cataract. Employee last eye exam was Oct 2020. No s/s of cataract noted at visit in October
Local (L) thigh-redness, 14x17 cm swelling and discomfort from upper thigh to knee area.  Involved thigh 2.5cm larger in circumference - secondary edema.
11:50am Post vaccination reports feeling cold, sweaty, lightheaded w/nausea; medical monitoring x 30 min; BP 160/90 P79 RR 19 12:24pm During medical monitoring expresses, "feels better" with no additional symptoms reported; BP 117/89 P66; released from facility w/self home
bruising - 2 days after second dose , soreness, bleeding while shaving, injection site 5cm bruise
Wife had patient in the bathroom and started screaming help. Patient's breathing very shallow. This nurse called 911. Put to bed immediately. No pulse. No respirations. At 10:25am CPR started. At 10:26am O2 applied. EMS here at 10:35am. Intubated at 10:37am. IV placed at 10:40am. EPI x 1 given at 10:41am. Another EPI x 1 given at 10:44am. Sodium bicarb given at 10:45am. Patient leaving with EMS. Blood pressure 171/130.Patient was at baseline this morning and vitals signs were in normal range. Patient was alert and oriented x 3.Patient took medications whole without complications. No complications noted.
PATIENT REFERS A BURNING SENSATION IN MOUTH AND THROAT. AN HOUR LATER BLISTERS APPEARED IN LIPS. THREE HOURS LATER BLEEDING GUMS. NEXT DAY REFERS HAVING A BAD HEADACHE.
While at clinic this morning  giving covid vaccines (Pfizer) nurse drew up 0.5ml instead of 0.3ml's. Was administered to patient!
Lichen Planopilaris, or frontal fibrosing alopecia. I am now taking doxycycline, 25 mg bid.
Pt received Tdap and Meningococcal vaccines. Pt felt dizzy and weak almost immediately after receiving injections. Pt remained seated and was monitored for 15 minutes or more. Once the pt was feeling better, she was released. Once released, she tool about 5-7 steps and fainted. When fainting occurred, the pts body became stiff, and seemed she may have had some brief seizure activity. She was attended to by the LVN who administered the vaccines, as well as assessed by the School Nurse. Once the student became fully conscious she was taken by wheel chair to the School Nurse's office, where she remained until released by school officials.
Typical side effect the next day or two; itching at injection site; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE PRURITUS (itching at injection site) and VACCINATION COMPLICATION (Typical side effect the next day or two) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 18-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 31-May-2021, the patient experienced VACCINATION SITE PRURITUS (itching at injection site). On an unknown date, the patient experienced VACCINATION COMPLICATION (Typical side effect the next day or two). At the time of the report, VACCINATION SITE PRURITUS (itching at injection site) and VACCINATION COMPLICATION (Typical side effect the next day or two) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Complaint of shortness of breath/difficulty breathing, elevated temperature, sore/scratchy throat, headache, runny nose/congestion, loss of taste and smell, myalgia, and malaise.
This case was reported by a healthcare professional and described the occurrence of rash in a 72-year-old male subject who was vaccinated with influenza virus vaccine (Fluarix) for prophylaxis. Medical history included no allergies (no egg allergy). There were no concurrent mediations. The subject had received influenza virus vaccine in previous years with no subsequent adverse events. On 27 October 2006 the subject received a dose of Fluarix in the left arm. On 27 October 2006, 8 hours after vaccination with Fluarix, the subject experienced redness and rash "primarily on the trunk, arms, and legs accompanied with severe itching". The subject was seen at a physician's office on 30 October 2006. Hematological analyses from 30 October 2006 revealed a normal sedimentation rate and complete blood count. At the time of initial reporting, 30 October 2006, the itching had improved and the redness and rash were ongoing. The healthcare professional considered the events were probably related to vaccination with Fluarix.
Breakthrough case admission after 5 vaccines Moderna 2/10/21 Lot# 015M20A; Moderna3/10/21 Lot# 030A21A;  Moderna 8/25/21 lot# 062E21A;  Moderna 5/16/22 lot# 059M21A;  Pfizer 10/26/22 lot# GH9703
Your shot almost killed me now; Vertigo; Stroke; heart cath; vision off; muscle soreness; muscle at base of my brain gets swollen; balance off; The initial case was missing the following minimum criteria: Unspecified product. Upon receipt of follow-up information on (28Mar2022), this case now contains all required information to be considered valid. This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 46 year-old male patient received bnt162b2 (BNT162B2), administration date 16Aug2021 (Lot number: EW01991) at the age of 46 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: NEAR DEATH EXPERIENCE (hospitalization, medically significant) with onset 25Aug2021, outcome "not recovered", described as "Your shot almost killed me now"; VERTIGO (hospitalization) with onset 25Aug2021, outcome "not recovered", described as "Vertigo"; CEREBROVASCULAR ACCIDENT (medically significant) with onset 25Aug2021, outcome "recovered" (2021), described as "Stroke"; VISUAL IMPAIRMENT (non-serious) with onset 2021, outcome "not recovered", described as "vision off"; MYALGIA (non-serious) with onset 2021, outcome "not recovered", described as "muscle soreness"; MUSCLE SWELLING (non-serious) with onset 2021, outcome "not recovered", described as "muscle at base of my brain gets swollen"; BALANCE DISORDER (non-serious) with onset 2021, outcome "not recovered", described as "balance off"; CATHETERISATION CARDIAC (non-serious) with onset 25Aug2021, outcome "recovered" (2021), described as "heart cath". Therapeutic measures were taken as a result of near death experience, vertigo, cerebrovascular accident, catheterisation cardiac.  Follow up (28Mar2022): This is a follow-up spontaneous report from a same contactable consumer. This consumer (patient) reported in response to non-HCP letter sent via follow-up letter which included that: New event, suspect product detail, was added   No follow-up attempts are possible. No further information is expected.
EXPIRED FLUMIST GIVEN TO CHILD DURING WELL CHILD EXAM.  NO REPORTED ADVERSE EVENTS TO DATE OF COMPLETING VAERS.
17 yo received an adult dose of the Havrix; 17 yo received an adult dose of the Havrix; expired on 6/14/2022; This case was reported by a other health professional via call center representative and described the occurrence of overdose in a 17-year-old female patient who received HAV (Havrix adult) (batch number X9A9B, expiry date 14th June 2022) for prophylaxis.   Co-suspect products included hepatitis A vaccine pre-filled syringe device (Havrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 19th August 2022, the patient received the 2nd dose of Havrix adult and Havrix Pre-Filled Syringe Device. On 19th August 2022, unknown after receiving Havrix adult and Havrix Pre-Filled Syringe Device, the patient experienced overdose, adult product administered to child and expired vaccine used. On an unknown date, the outcome of the overdose, adult product administered to child and expired vaccine used were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 24-Aug-2022 Reporter's comments: The healthcare professional reported that the patient received an adult dose of the Havrix and it was also expired on 14th June 2022.  This was the 2nd dose in the series.  There were no reactions reported.  The vaccine administration facility was the same as primary reporter.  The reporter consent to follow-up via email. Additional Supportive Information: The 17 years old patient received expired adult dose of Havrix, which led to overdose, adult product administered to child and expired vaccine used.
This case was reported by a nurse via call center representative and described the occurrence of therapy non-responder in a child female patient who received ENGERIX B pediatric. Co-suspect products included ENGERIX B pediatric, ENGERIX B pediatric and ENGERIX B pediatric (batch number N45BR, expiry date 3rd September 2015). On an unknown date, the patient received the 1st dose of ENGERIX B pediatric, the 2nd dose of ENGERIX B pediatric and the 3rd dose of ENGERIX B pediatric. On 16th September 2015, the patient received the 5th dose of ENGERIX B pediatric .5 ml. On 16th September 2015, not applicable after receiving ENGERIX B pediatric, ENGERIX B pediatric and ENGERIX B pediatric and an unknown time after receiving ENGERIX B pediatric, the patient experienced expired vaccine used. On an unknown date, the patient experienced therapy non-responder. On an unknown date, the outcome of the therapy non-responder and expired vaccine used were unknown. It was unknown if the reporter considered the therapy non-responder to be related to ENGERIX B pediatric, ENGERIX B pediatric and ENGERIX B pediatric. Additional details provided were as follows: On unspecified dates, as a child, the patient received 3 doses of ENGERIX B pediatric. On an unknown date, the patient performed test for Hepatitis B antibody, which was found to be negative, causing the patient to be a non-responder to therapy. On an unknown date, the patient was revaccinated with ENGERIX B pediatric as a 4th dose. On 16th September 2015, at 10:30, the patient received 5th dose in series (2nd dose of revaccination), which had already expired on 3rd September 2015. There were no adverse events reported till date.